Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
SEHK:2315 Stock Report
Biocytogen Pharmaceuticals (Beijing) Future Growth
Future criteria checks 2/6
Biocytogen Pharmaceuticals (Beijing) is forecast to grow revenue at 22.4% per annum.
Key information
| Biotechs earnings growth | 43.0% |
| Revenue growth rate | 22.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 Nov 2024 |
Recent future growth updates
Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment?
May 08Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking
Apr 03Earnings and Revenue Growth Forecasts
SEHK:2315 - Analysts future estimates and past financials data (CNY Millions)| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|
| 12/31/2026 | 1,410 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 1,216 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 947 | N/A | N/A | N/A | 1 |
| 6/30/2024 | 801 | -244 | -88 | -29 | N/A |
| 3/31/2024 | 759 | -313 | -146 | -53 | N/A |
| 12/31/2023 | 717 | -383 | -203 | -77 | N/A |
| 9/30/2023 | 674 | -451 | -304 | -143 | N/A |
| 6/30/2023 | 632 | -519 | -404 | -210 | N/A |
| 3/31/2023 | 583 | -561 | -474 | -256 | N/A |
| 12/31/2022 | 534 | -602 | -544 | -303 | N/A |
| 9/30/2022 | 493 | -585 | -538 | -312 | N/A |
| 6/30/2022 | 453 | -569 | -532 | -320 | N/A |
| 3/31/2022 | 404 | -557 | -548 | -343 | N/A |
| 12/31/2021 | 355 | -546 | -564 | -366 | N/A |
| 12/31/2020 | 254 | -217 | -522 | -225 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 2315's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 2315's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 2315's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 2315's revenue (22.4% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 2315's revenue (22.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2315's Return on Equity is forecast to be high in 3 years time
Discover growth companies
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
